Skip to main content
Equibles
BLFS logo

BLFS · Biolife Solutions Inc · Metrics

Track BLFS — free

Use BLFS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BLFS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$38.61 +1.31 (+3.51%) At close · Oct 5
Rebalance outlook locked
Market Cap
$1.89B
Shares
48.91M
Volume · Oct 5 4.45M Avg daily vol (3M) 1.12M

BLFS metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$38.61
Market cap
$1.89B

Price action

20 metrics
Price change (1W)
-1.4%
Price change (30D)
-1.4%
Price change (3M)
+38.9%
Price change (6M)
+100.4%
Price change (YTD)
+59.7%
Price change (1Y)
+45.2%
Trailing year
Price change (5Y)
—
52-week high
$39.22
52-week low
$18.15
Change from 52-week high
-1.6%
Change from 52-week low
+112.7%
Annualized volatility
43.7%
Annualized volatility (3M)
35.3%
Beta
1.1
RSI (14D)
60.6
Price vs SMA 50
+8.2%
Price vs SMA 200
+45.0%
Avg volume (3M)
1.12M
Relative volume
4.0
Average dollar volume
$38.22M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
48.91M

Valuation

12 metrics
P / E (TTM)
33.3
Trailing earnings · reciprocal yield 3.0%
PEG ratio
—
EV / revenue
17.5×
reciprocal yield 5.7%
EV / EBITDA
543.8×
reciprocal yield 0.2%
EV / EBIT
1,067.7×
reciprocal yield 0.1%
P / sales
17.7×
reciprocal yield 5.6%
P / book
4.5
reciprocal yield 22.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
111.9
reciprocal yield 0.9%
Earnings yield
3.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
9.3×
reciprocal yield 10.8%
EV / revenue historical average (5Y)
9.4×
reciprocal yield 10.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-07

Profitability

9 metrics
Gross margin
64.6%
Operating margin
1.6%
Trailing 12 months
Net margin
54.3%
Gross profit (TTM)
$67.87M
Operating profit (TTM)
$1.75M
Net income (TTM)
$57.98M
Trailing 12 months
Diluted EPS (TTM)
$1.16
FCF margin
—
Effective tax rate
-620.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$2.17
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$0.04
EBITDA per diluted share (TTM)
$0.07
Net income per diluted share (TTM)
$1.17
Operating cash flow per diluted share (TTM)
$0.34
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.20
Stock compensation per diluted share (TTM)
$0.44
Book value per share
$7.72

Growth

11 metrics
Revenue growth YoY
+21.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$106.69M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.1%
Year over year · more shares
Revenue CAGR (3Y)
+8.1%
Revenue CAGR (5Y)
+14.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+17.8%

Quality

14 metrics
Return on equity
13.8%
Return on assets
13.0%
Debt / equity
0.0
Current ratio
9.7
EBITDA (TTM)
$3.43M
Free cash flow (TTM)
—
Quick ratio
7.1
Interest coverage
—
Net debt / EBITDA
-7.0
Return on invested capital
—
Trailing 12 months
Net cash
$24.00M
Latest balance sheet
Cash & equivalents
$24.00M
Total assets
$447.49M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$16.88M
Capital expenditures (TTM)
$8.77M
R&D (TTM)
$9.77M
SG&A (TTM)
—
Stock compensation (TTM)
$21.64M
R&D / revenue
9.2%
Stock compensation / revenue
20.3%

Ownership (13F)

9 metrics
13F filers
216
13F filer change QoQ
+29
Institutional ownership
101.4%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-3.6%
Holder tenure
15.2
Price vs estimated holder cost
+14.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.5%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 834365 CUSIP 09062W204 13F (30d) 38 filings 37 filers Visit website Investor relations